SCHOTT Pharma stock faces pressure amid slow growth and margin squeeze in pharma packaging sector

SCHOTT Pharma, a leading provider of primary packaging solutions for injectable drugs, reported its full-year 2025 results this week, revealing revenue growth of just 2.3% to €940 million on the Frankfurt Stock Exchange-listed stock (ISIN: DE000A3ENQ51). The modest top-line expansion fell short of consensus expectations, driven by weaker demand in high-value drug delivery systems amid global supply chain adjustments in the pharmaceutical industry. For US investors, this underscores vulnerabilities in European medtech firms reliant on biotech pipelines, where delays in drug approvals and production ramps have cascaded into packaging orders.

As of: 25.03.2026

Dr. Elena Voss, Senior Pharma Packaging Analyst: In a sector buoyed by biologics demand, SCHOTT Pharma's results signal caution for investors tracking the intersection of drug innovation and supply chain resilience.

Disappointing Full-Year Results Trigger Selloff

SCHOTT Pharma's 2025 annual figures, released on March 23, 2026, showed adjusted EBITDA of €210 million, a 1.8% decline from the prior year despite cost-saving initiatives. The company cited higher raw material costs and currency headwinds as primary drags, with the SCHOTT Pharma stock dropping 4.2% to €28.50 in EUR on Xetra in Frankfurt on the announcement day. Management maintained its 2026 guidance for mid-single-digit revenue growth but trimmed EBITDA margin expectations to 22-24% from previous 23-25%, reflecting ongoing pricing pressures from major pharma clients.

The packaging giant, spun off from SCHOTT AG in 2023, specializes in glass vials, syringes, and cartridges critical for mRNA vaccines and biologics. While COVID-related tailwinds have faded, new GLP-1 weight-loss drugs from partners like Novo Nordisk offered hope, but order deferrals linked to clinical trial delays hurt volumes. On the Frankfurt Stock Exchange, the SCHOTT Pharma stock has underperformed the MDAX index by 15% over the past year, trading at a forward P/E of 18x versus sector peers at 22x.

Operational Breakdown Reveals Margin Erosion

Breaking down the numbers, SCHOTT Pharma's Drug Delivery Systems division, which accounts for 60% of revenue, grew 3% but saw EBITDA margins compress to 25% from 27% due to investments in new production lines for polymer syringes. The Pharmaceutical Systems segment stagnated at €370 million, hit by lower vials demand post-pandemic. Capex remained elevated at €150 million, funding expansions in Europe and Asia to meet anticipated biologics surge, but ROI timelines have stretched amid slower client ramps.

Regional dynamics played a role: North America, contributing 30% of sales, faced headwinds from US FDA inspections delaying partner drug launches, while EMEA grew steadily on insulin packaging strength. Management highlighted €20 million in savings from digitalization but warned of €15 million in additional energy costs through 2026. The SCHOTT Pharma stock reaction on Xetra reflected this, with trading volume spiking 250% above average as funds trimmed positions.

Strategic Initiatives Amid Pharma Sector Headwinds

SCHOTT Pharma is pushing sustainability with recyclable glass packaging, aligning with EU regulations and client ESG demands. A new €100 million facility in India targets emerging markets, while partnerships with US biotech firms like Moderna for next-gen vials position it for mRNA revival. However, competition from Stevanda and Gerresheimer intensifies, with peers gaining share through aggressive pricing.

Balance sheet remains solid with net debt to EBITDA at 1.8x and €250 million in cash, supporting buybacks or dividends. CEO Dirk Fuhrmann emphasized pipeline visibility for 40 new drug projects, but execution risks loom if inflation persists. For the SCHOTT Pharma stock on Frankfurt, this mix supports a hold rating from most analysts, with average targets at €32.

US Investor Relevance: Exposure to Biologics Boom

US investors should watch SCHOTT Pharma for its ties to American pharma giants. Over 25% of revenue stems from US clients, including Pfizer and Eli Lilly, whose GLP-1 portfolios drive packaging needs. As the US biologics market grows 12% annually per IQVIA data, SCHOTT's specialized glass tech offers leveraged play without direct drug risk.

Listed on Xetra in EUR, the stock provides diversification from Nasdaq-heavy medtech via European exchanges accessible through ADRs or OTC. Amid US rate cuts boosting growth stocks, SCHOTT's 5% dividend yield appeals to income seekers. However, currency swings—EUR/USD at 1.08—add volatility, with a 10% euro weakening eroding returns by 3%.

Risks and Open Questions for 2026

Key risks include raw glass price hikes—up 8% YoY—and potential US-China trade tensions disrupting boron supply. Patent expirations on partner drugs could cut volumes 5-7%, while regulatory scrutiny on glass defects poses recall risks. If biologics demand accelerates slower than expected, capex overhang pressures free cash flow to €80 million from €100 million guided.

Analyst divergence exists: optimists cite 15% CAGR in drug delivery to 2030, pessimists flag overcapacity. Macro factors like persistent inflation or delayed Fed cuts could cap multiples. Investors must monitor Q1 results on May 15 for early signs of inflection.

Valuation and Outlook: Buy the Dip?

At €28.50 on Xetra, SCHOTT Pharma trades at 1.2x sales and 13x EV/EBITDA, discounting growth to 7% CAGR. Consensus targets imply 20% upside, but execution is key. For US portfolios, it fits as a defensive medtech pick with global reach.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.